Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Aquestive Therapeutics Inc (NASDAQ: AQST) closed at $3.52 up 7.32% from its previous closing price of $3.28. In other words, the price has increased by $7.32 from its previous closing price. On the day, 1.7 million shares were traded. AQST stock price reached its highest trading level at $3.54 during the session, while it also had its lowest trading level at $3.26.
Ratios:
For a deeper understanding of Aquestive Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.87 and its Current Ratio is at 2.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on April 11, 2024, initiated with a Overweight rating and assigned the stock a target price of $10.
On March 28, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 15 ’24 when Schobel Alexander Mark sold 50,000 shares for $6.00 per share. The transaction valued at 300,000 led to the insider holds 984,476 shares of the business.
Schobel Alexander Mark sold 25,000 shares of AQST for $129,685 on Mar 08 ’24. The Chief Innovation/Tech Officer now owns 1,040,371 shares after completing the transaction at $5.19 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 320455520 and an Enterprise Value of 267467232. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.93. Its current Enterprise Value per Revenue stands at 5.288 whereas that against EBITDA is -19.48.
Stock Price History:
The Beta on a monthly basis for AQST is 2.86, which has changed by 0.45777774 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -16.21%, while the 200-Day Moving Average is calculated to be 40.66%.
Shares Statistics:
For the past three months, AQST has traded an average of 2.82M shares per day and 2836250 over the past ten days. A total of 85.20M shares are outstanding, with a floating share count of 75.56M. Insiders hold about 11.31% of the company’s shares, while institutions hold 28.00% stake in the company. Shares short for AQST as of 1713139200 were 4008551 with a Short Ratio of 1.42, compared to 1710460800 on 2315549. Therefore, it implies a Short% of Shares Outstanding of 4008551 and a Short% of Float of 5.35.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Aquestive Therapeutics Inc (AQST).On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.04 and a low estimate of -$0.12, while EPS last year was $0.11. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.27 and -$0.45 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.3, with 6.0 analysts recommending between -$0.12 and -$0.47.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $12.26M this quarter.It ranges from a high estimate of $13M to a low estimate of $10.9M. As of the current estimate, Aquestive Therapeutics Inc’s year-ago sales were $11.13MFor the next quarter, 8 analysts are estimating revenue of $12.6M. There is a high estimate of $13.1M for the next quarter, whereas the lowest estimate is $12M.
A total of 8 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $52M, while the lowest revenue estimate was $48.1M, resulting in an average revenue estimate of $50.21M. In the same quarter a year ago, actual revenue was $43.8MBased on 7 analysts’ estimates, the company’s revenue will be $57.98M in the next fiscal year. The high estimate is $77M and the low estimate is $49.8M.
